|
Dr. Andrew P. Krivoshik, MD, PhD,
PE
Andrew P. Krivoshik, MD, PhD, PE is
a Medical Director with the Oncology
Group, Global Pharmaceutical
Research and Development, Abbott
Laboratories, where his
responsibilities include the
translational and early clinical
development of the Bcl-2 family
protein inhibitor program. Dr.
Krivoshik transitioned into
pharmaceutical development from
academic medicine through Abbott’s
Physician Development Program (PDP).
While in the PDP, Dr. Krivoshik
obtained comprehensive exposure to
pharmaceutical development,
including serving as principal
investigator in the clinical
pharmacology Phase I research unit,
functioning as a pharmacovigilance
physician in both post marketing and
clinical IND safety, performing
outcomes research, and has
subsequently transitioned into
global oncology clinical
development. Dr. Krivoshik has
provided key medical support in
preparation for FDA ODAC
presentation, assisted in cytotoxic
pediatric development in
collaboration with pediatric
cooperative groups, and has provided
medical support for cytotoxic and
targeted therapy IND and CTA
submissions including first in human
and pediatric protocol development.
Prior to joining Abbott, Dr.
Krivoshik was recruited by Duke
University Medical Center (DUMC) as
the Jim Valvano Post-Doctoral Fellow
in Pediatric Cancer Research through
the V Foundation for Pediatric
Cancer Research, where his research
in cancer biology focused on
vasomotor activity using skin fold
window chamber tumor models. Dr.
Krivoshik completed clinical
residency training in Pediatric and
Adolescent Medicine at the Mayo
Clinic and subspecialty fellowship
training in Pediatric
Hematology-Oncology at DUMC. He is
board certified as a Diplomate of
the American Board of Pediatrics and
is licensed in several jurisdictions
both as a Physician as well as a
Professional Engineer. He has
received many awards and honors,
including a US Public Health Service
Award for Pre-doctoral Individual
MD/PhD Fellows, and has been
identified twice as a “Service
Champion” at DUMC. He holds a BSE in
Electrical Engineering with Honors
from Princeton University, and both
an MD and a PhD in Biophysics and
Computational Biology from the
University of Illinois at
Urbana-Champaign (UIUC), where his
research focused on smooth muscle
biomechanical signal transduction.
In addition to lecturing, Dr.
Krivoshik has published research
articles in biomedical areas, and
remains an active member of several
professional societies. He has
participated in various professional
consulting relationships, including
serving on the UIUC College of
Medicine inaugural Dean’s Advisory
Board, and before entering academic
medicine, worked in a research
position at the IBM Thomas J. Watson
Research Center. |
